(Q37861894)

24 August 2017

1 reference

title

The role of antiplatelets in hypertension and diabetes mellitus (English)

1 reference

24 August 2017

main subject

arterial hypertension

0 references

author name string

R A Ajjan

series ordinal

1

1 reference

24 August 2017

Peter J Grant

series ordinal

2

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Journal of Clinical Hypertension

24 August 2017

published in

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

305-313

1 reference

Metabolic syndrome pandemic.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Best strategies for hypertension management in type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Aspirin as antiplatelet agent in diabetes: Cons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Diabetes and acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Risk factors for intracerebral hemorrhage in the general population: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Racial variations in location and risk of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Antiplatelet drugs and risk of subarachnoid hemorrhage: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7176.2011.00431.X

10.1111/J.1751-7176.2011.00431.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference